Investors are often intrigued by ETFs that feature sky-high dividend yields, such as the Amplify High Income ETF (NYSEARCA:YYY), which currently yields 12.3%.While the thought of receiving passive ...

California has nine income tax rates, ranging from 1% to 12.3%. Learn more about how to calculate your bill, plus when taxes are due. Many, or all, of the products featured on this page are from ...

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.1% year on year to $233.4 million. On the other hand ...

Forbes contributors publish independent expert analyses and insights. Shelley E. Kohan covers the retail industry and is based in New York. Ulta Beauty CEO Dave Kimbell discussed the company’s ...

RYLD has dropped over the last 7 months. Total return has done better, but the fund has only returned about 3.1% annually since inception. We go over why and tell you how we are making income ...

Forbes contributors publish independent expert analyses and insights. Brett uses “second-level thinking” to find dividend stocks to buy.

There were even greater disparities for those living in poverty. Most American adults are not getting enough of their fruits and vegetables, according to a new study from the Centers for Disease ...

Dillard's beat earnings projections but missed on revenue. The stock got downgraded by a major analyst. Retailer Dillard's has been pretty resilient over the past year amid the headwinds of ...

With an R&D spend, up 16% from FY24, Akums continues to deepen its innovation capabilities, develop complex formulations, and enrich its portfolio. The company's emphasis on quality-focused ...

Alberta Investment Management Corp. reported a 12.3-per-cent return across its funds in 2024 but fell short of its internal benchmark of 13.8 per cent, capping off a year that ended in turmoil ...

The TSX’s great start this month signals a new buying season. Canada’s main stock index hit a one-month high at the close on May 2. Trade tensions could likewise ease in the coming days as ...

In 2023, the myotonic dystrophy treatment market is projected to be worth USD 874.39 million. The global demand for myotonic dystrophy treatment is anticipated to increase at a CAGR of 12.3% between ...